Denali Therapeutics (DNLI) Non-cash Items (2017 - 2018)

Denali Therapeutics (DNLI) reported Non-cash Items of $95.8 million for Q1 2018, up 23.89% quarter-over-quarter from $77.3 million in Q4 2017.

Denali Therapeutics (DNLI) Non-cash Items (2017 - 2018) Analysis & Trends

Denali Therapeutics (DNLI) has 2 years of Non-cash Items data on file, last reported at $95.8 million in Q1 2018.

Non-cash Items for Q1 2018 came in at $95.8 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2018 was $95.8 million (changed N/A YoY), and the FY2017 annual result was $77.3 million, changed N/A from the prior year.
Non-cash Items advanced to $95.8 million in Q1 2018 per DNLI's latest filing, from $77.3 million in the prior quarter.
Over five years, Non-cash Items peaked at $95.8 million in Q1 2018 and troughed at $77.3 million in Q4 2017.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Denali Therapeutics	4.35 Bn	4.35 Bn	-

Download Data